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Identification of a range of targets essential and specific for
tumour progression has resulted in a new generation of anticancer
agents, the molecular-targeted therapies. Of these, agents that
inhibit specific growth factors, such as epidermal growth factor
(EGF) and vascular endothelial growth factor (VEGF), have shown
particular promise and are now available for use in patients. In this
supplement we explore the potential of molecular-targeted agents
and highlight specific considerations as an increasing number are
clinically approved.
In the first of these articles, Roy Bicknell reviews the key
molecular targets for novel antitumour agents and the challenge of
translating the early promise of this new class of drugs into clinical
practice. The wealth of in vitro and in vivo data obtained with
ZD6474, a selective inhibitor of VEGF and EGF receptor tyrosine
kinase activity, is reviewed by Anderson Ryan and Stephen Wedge.
The clinical evaluation of ZD6474 to date is summarised by John V
Heymach, who highlights the successes of the Phase I studies and
discusses the ongoing Phase II programme, which aims to evaluate
the clinical value of this agent alone and in combination with
certain chemotherapy regimens.
I have elected to review the role of novel targeted therapies in
the clinic, their current use, potential toxicity issues and finally
what I have called the What?, When? How? and Who? of targeted
therapy. As such, I attempt to distil our current knowledge and
discuss how we might use these agents to best effect. Finally,
Malcolm Ranson and Gordon Jayson consider the future of
targeted therapy, highlighting the need for closer integration of
preclinical and clinical data, a greater use of genomic and
proteomic techniques, and further refinement of clinical trial
design.
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